A study comparing renal and bone outcomes of Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate with other Tenofovir disoproxil fumarate regimens in treatment-naive HIV-infected veterans

Trial Profile

A study comparing renal and bone outcomes of Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate with other Tenofovir disoproxil fumarate regimens in treatment-naive HIV-infected veterans

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Cobicistat; Elvitegravir; Emtricitabine; Emtricitabine/tenofovir disoproxil fumarate; Rilpivirine; Tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top